Evidence map›Paper›PMID 41742835›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Deciphering the Impact of RAC1-SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models.

Shohei Kuraoka, Yuhei Higashi, Suguru Saito, Solmaz Pourgonabadi, Honami Honjoh, Sho Ishigaki, Peter C Harris, Lisa M Satlin, Michifumi Yamashita, Ryuji Morizane

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shohei KuraokaDivision of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Yuhei HigashiDivision of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Suguru SaitoDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Solmaz PourgonabadiDivision of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Honami HonjohDivision of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Sho IshigakiDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Peter C HarrisDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Lisa M SatlinDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Michifumi YamashitaDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Ryuji MorizaneDivision of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-0377-5667

Funding

Resource Development CoreU54DK137329 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Gerard L Apodaca · 2023 to 2026
$4.8M
Recreating Kidney Organogenesis in vitro with Human Pluripotent Stem CellsDP2DK133821 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MORIZANE, RYUJI · 2019 to 2019
$2.5M
Vascularized kidney organoids on chip for efficacy and toxicity testing of somatic genome editingU01DK127587 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI LEWIS, JENNIFER A., MORIZANE, RYUJI · 2020 to 2022
$2.1M
Understanding renal intrinsic repair by FANCD2R01DK141567 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ryuji Morizane · 2025 to 2026
$1.3M
Development of a fluidic chip model of PKD to elucidate cystogenic signals using kidney organoidsR21DK129909 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MORIZANE, RYUJI · 2022 to 2022
$216k
NIDDK NIH HHS DP2 DK133821NIDDK NIH HHS R01 DK141567NIDDK NIH HHS R21 DK129909NIDDK NIH HHS U01 DK127587NIDDK NIH HHS U54 DK137329NIH HHS DP2EB029388/DK133821NIH HHS R01DK141567NIH HHS R21DK129909NIH HHS U01EB028899/DK127587
6 · The paper itself

Abstract

Autosomal recessive polycystic kidney disease (ARPKD) leads to severe renal cysts and progressive kidney dysfunction, with no approved treatments. The absence of such cystic phenotypes in Pkhd1

Indexed as

Microfilament ProteinsNeuropeptidesPolycystic Kidney, Autosomal Recessiverac1 GTP-Binding ProteinAnimalsDisease Models, AnimalHumansMiceMice, TransgenicMicrofilament ProteinsNeuropeptidesrac1 GTP-Binding ProteinRac1 protein, mousekidneynephronorganoidorgan‐on‐chippolycystic kidney diseaseRAC1SPTAN1

Identifiers

PMID41742835
PMCPMC13137809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.